Publications

Born, P., Fandrei, D., Wang, S. Y., Perez-Fernandez, C., Fischer, L., Ussmann, J., Bach, E., Hoffmann, S., Metzeler, K. H., Herling, M., Herling, C., Jentzsch, M., Boldt, A., Seiffert, S., Baber, R., Weidner, H., Franke, G. N., Denecke, T., Sabri, O., Platzbecker, U., … Merz, M. (2025). Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma. HemaSphere, 9(6), e70159. https://doi.org/10.1002/hem3.70159

Merz, M., Gagelmann, N., Smaili, S., Flossdorf, S., Sauer, S., Scheid, C., von Tresckow, B., Wulf, G. G., Weisel, K. C., Blau, I., Engelhardt, M., Wäsch, R., Schub, N., Teipel, R., Hecker, J. S., Waldschmidt, J. M., Besemer, B., Baermann, B. N., Call, S., Hansmann, L., … Kröger, N. (2025). Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST. Blood, blood.2025028330. Advance online publication. https://doi.org/10.1182/blood.2025028330

Ferle, M., Grieb, N., Kreuz, M., Ader, J., Goldschmidt, H., Mai, E. K., Bertsch, U., Platzbecker, U., Neumuth, T., Reiche, K., Oeser, A., & Merz, M. (2025). Predicting progression events in multiple myeloma from routine blood work. NPJ digital medicine, 8(1), 231. https://doi.org/10.1038/s41746-025-01636-9

Braun, T., Kuschel, F., Reiche, K., Merz, M., & Herling, M. (2025). Emerging T-cell lymphomas after CAR T-cell therapy. Leukemia, 39(6), 1337–1341. https://doi.org/10.1038/s41375-025-02574-x

Braun, T., Rade, M., Merz, M., Klepzig, H., Große, F., Fandrei, D., Pham, N. N., Kreuz, M., Kuhn, C. K., Kuschel, F., Löffler, D., Meinel, J., Heger, E., Schweinsberg, V., Pflug, N., Platzbecker, U., Hallek, M., Holtick, U., Köhl, U., Scheid, C., … Richardson, T. (2025). Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody. Nature medicine, 31(4), 1145–1153. https://doi.org/10.1038/s41591-025-03499-9